<DOC>
	<DOCNO>NCT01290146</DOCNO>
	<brief_summary>The purpose study compare patient Advanced Chronic Heart Failure effect Levosimendan versus diuretic ( single 24-hour infusion ) apply early detection impend destabilization hospitalization-free survival 12 month . Patients advance chronic heart failure ( ACHF ) short term reduce life expectancy recurrent hospital admission clinical exacerbation . Levosimendan improve contractility calcium-dependent binding troponin C , determine vasodilation coronary artery systemic resistance vessel , thus decrease preload afterload , exert protective effect myocardium ischemia-reperfusion damage . In randomized clinical trial acute heart failure patient , levosimendan improved hemodynamics patient ' quality life decrease natriuretic peptide plasma level , excess mortality The study ass whether administration levosimendan ( single 24-hour infusion ) early detection deterioration may reduce frequency duration hospital admission , improve functional status quality life ACHF patient , respect diuretic infusion .</brief_summary>
	<brief_title>ELEVATE Early LEvosimendan Vs Usual Care Advanced Chronic hearT failurE</brief_title>
	<detailed_description>BACKGROUND Patients advance chronic heart failure ( ACHF ) short term reduce life expectancy recurrent hospital admission clinical exacerbation . ACHF pose heavy burden cardiology department , patient refer severity clinical condition , require specialist approach , result high health care cost due frequent rehospitalizations . Patients ACHF ≥ 2 hospital admission 6 month high risk recurrent exacerbation . The benefit strict outpatient follow-up specialise HF v standard community care ACHF patient consistently demonstrate . The standard approach HF clinic base flexible diuretic dose outpatient iv diuretic bolus infusion early sign decompensation . Although strategy result symptomatic benefit prevents approximately one third hospital admission acute exacerbation , relevant proportion patient still need hospitalization . Predictors lack benefit low systolic blood pressure , prior increase oral diuretic beta-blocker use , take together represent marker severe disease susceptible evolve low output state . In HF clinic setting , novel strategy patient , include early support myocardial contractility , i.e . compel criteria hospital admission become manifest , might prevent prolonged hospitalization , myocardial damage impairment renal function TRIAL RATIONALE Levosimendan improve hemodynamics patient ' quality life decrease natriuretic peptide plasma level , excess mortality , randomize clinical trial acute heart failure . In SURVIVE early large treatment effect levosimendan apparent patient acute worsen chronic HF treatment de novo disease , possibly great proportion patient may beta-blockers , know interfere dobutamine may potentiate circulatory action levosimendan . Thus levosimendan may unattractive first-line agent destabilize ACHF patient beta-blockers . Based drug cardioprotective property , hemodynamic neurohormonal effect , propose novel therapeutic approach clinically-driven use levosimendan recurrent acute exacerbation ACHF . Dosing drug omit bolus increase tolerability severely ill patient population .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Diuretics</mesh_term>
	<mesh_term>Simendan</mesh_term>
	<criteria>Written inform consent Systolic dysfunction ( LVEF ≤ 35 % echo assessment within 6 month enrolment ) No requirement hospital admission diagnostic work elective treatment define etiology and/or treatment plan Already optimal standard HF treatment base individual tolerance , include cardiac resynchronization therapy ( CRT ) /ICD device accord current guideline At least 2 hospital admission HF 6 month enrolment , recent one within 3090 day enrolment requirement inotrope administration Participant study last 30 day Life expectancy &lt; 1 year comorbid condition HF Pregnancy , lactation , childbearing potential unless adequate contraception Acute coronary syndrome , percutaneous surgical revascularization , valve surgery perform within 8 week enrolment Planned percutaneous surgical procedure ( except heart transplantation ) CRT within 6 month enrolment Cardiogenic shock Supine systolic BP &lt; 85 mmHg Severe liver insufficiency ( &gt; threefold increase ASTALT ) Sever chronic kidney dysfunction ( estimate GFR &lt; 30 ml/min ) Sustained ventricular tachycardia Severe chronic current acute infection ( temperature &gt; 38 C , WBC &gt; 15,000/mm3 ) Severe chronic obstructive pulmonary disease ( FEV1 &lt; 30 % predict oxygen therapy ) Severe persistent anemia ( Hb &lt; 10 g/l ) ) ACHF exacerbation due condition require specific treatment ( e.g . anemia , atrial fibrillation , supraventricular tachycardia ) Documented low compliance unavailable program followup visit phone contact</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Heart Failure</keyword>
	<keyword>Levosimendan</keyword>
	<keyword>Inotropic agent</keyword>
	<keyword>Phosphodiesterase Inhibitors</keyword>
	<keyword>Vasodilators</keyword>
	<keyword>Diuretics</keyword>
</DOC>